Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer
BeiGene
BeiGene
ALX Oncology Inc.
Spanish Oncology Genito-Urinary Group
Imugene Limited
Genentech, Inc.
Altor BioScience
European Organisation for Research and Treatment of Cancer - EORTC
Canadian Cancer Trials Group
Eastern Cooperative Oncology Group
Nektar Therapeutics
Pfizer
Eli Lilly and Company
H. Lee Moffitt Cancer Center and Research Institute
AIO-Studien-gGmbH
AbbVie
AstraZeneca
Eli Lilly and Company
China Medical University Hospital
Eli Lilly and Company
University of California, San Diego
National University Hospital, Singapore
Amgen
AstraZeneca
Ohio State University Comprehensive Cancer Center
CanBas Co. Ltd.
Altor BioScience
Memorial Sloan Kettering Cancer Center
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Centro Nacional de Investigaciones Oncologicas CARLOS III
University Hospital of Crete
Fudan University
UNICANCER
Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany
Amgen
European Organisation for Research and Treatment of Cancer - EORTC
Pomeranian Medical University Szczecin
Mayo Clinic
Sanofi
Johannes Gutenberg University Mainz